Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 157 to 168 of 168 entries
Sorted by: Best Match Show Resources per page
An Affordable Fabrication of a Zeolite-Based Capacitor for Gas Sensing.

Sensors (Basel, Switzerland)

Pullano SA, Falcone F, Critello DC, Bianco MG, Menniti M, Fiorillo AS.
PMID: 32290282
Sensors (Basel). 2020 Apr 10;20(7). doi: 10.3390/s20072143.

The development of even more compact, inexpensive, and highly sensitive gas sensors is widespread, even though their performances are still limited and technological improvements are in continuous evolution. Zeolite is a class of material which has received particular attention...

Cite
Pullano SA, Falcone F, Critello DC, et al. An Affordable Fabrication of a Zeolite-Based Capacitor for Gas Sensing. Sensors (Basel). 2020;20(7)doi: 10.3390/s20072143.
Pullano, S. A., Falcone, F., Critello, D. C., Bianco, M. G., Menniti, M., & Fiorillo, A. S. (2020). An Affordable Fabrication of a Zeolite-Based Capacitor for Gas Sensing. Sensors (Basel, Switzerland), 20(7), . https://doi.org/10.3390/s20072143
Pullano, Salvatore Andrea, et al. "An Affordable Fabrication of a Zeolite-Based Capacitor for Gas Sensing." Sensors (Basel, Switzerland) vol. 20,7 (2020). doi: https://doi.org/10.3390/s20072143
Pullano SA, Falcone F, Critello DC, Bianco MG, Menniti M, Fiorillo AS. An Affordable Fabrication of a Zeolite-Based Capacitor for Gas Sensing. Sensors (Basel). 2020 Apr 10;20(7). doi: 10.3390/s20072143. PMID: 32290282; PMCID: PMC7180832.
Copy Download .nbib Format: NLM
First Report of Compound Heterozygosity for Hb S (.

Hemoglobin

Ogu UO, Reyes Gil M, Tolu SS, Acharya SA, Minniti CP.
PMID: 34134586
Hemoglobin. 2021 Mar;45(2):136-139. doi: 10.1080/03630269.2021.1926276. Epub 2021 Jun 16.

Sickle cell disease variants include hemoglobinopathies that result from inheritance of the sickle cell globin mutation with another globin mutation. The most common variants include the homozygous disease state (Hb SS disease), Hb S (

Cite
Ogu UO, Reyes Gil M, Tolu SS, et al. First Report of Compound Heterozygosity for Hb S (. Hemoglobin. 2021;45(2):136-139doi: 10.1080/03630269.2021.1926276.
Ogu, U. O., Reyes Gil, M., Tolu, S. S., Acharya, S. A., & Minniti, C. P. (2021). First Report of Compound Heterozygosity for Hb S (. Hemoglobin, 45(2), 136-139. https://doi.org/10.1080/03630269.2021.1926276
Ogu, Ugochi O, et al. "First Report of Compound Heterozygosity for Hb S (." Hemoglobin vol. 45,2 (2021): 136-139. doi: https://doi.org/10.1080/03630269.2021.1926276
Ogu UO, Reyes Gil M, Tolu SS, Acharya SA, Minniti CP. First Report of Compound Heterozygosity for Hb S (. Hemoglobin. 2021 Mar;45(2):136-139. doi: 10.1080/03630269.2021.1926276. Epub 2021 Jun 16. PMID: 34134586.
Copy Download .nbib Format: NLM
Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases.

Journal for immunotherapy of cancer

Minniti G, Lanzetta G, Capone L, Giraffa M, Russo I, Cicone F, Bozzao A, Alongi F, Nicosia L, Fineschi G, Marchetti L, Tufo T, Bianciardi F, Esposito V, Gentile P, Paolini S.
PMID: 34949695
J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003730.

PURPOSE: Immunotherapy has shown activity in patients with brain metastases (BM) and leptomeningeal disease (LMD). We have evaluated LMD and intraparenchymal control rates for patients with resected BM receiving postoperative stereotactic radiosurgery (SRS) and immunotherapy or postoperative SRS alone....

Cite
Minniti G, Lanzetta G, Capone L, et al. Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases. J Immunother Cancer. 2021;9(12)doi: 10.1136/jitc-2021-003730.
Minniti, G., Lanzetta, G., Capone, L., Giraffa, M., Russo, I., Cicone, F., Bozzao, A., Alongi, F., Nicosia, L., Fineschi, G., Marchetti, L., Tufo, T., Bianciardi, F., Esposito, V., Gentile, P., & Paolini, S. (2021). Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases. Journal for immunotherapy of cancer, 9(12), . https://doi.org/10.1136/jitc-2021-003730
Minniti, Giuseppe, et al. "Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases." Journal for immunotherapy of cancer vol. 9,12 (2021). doi: https://doi.org/10.1136/jitc-2021-003730
Minniti G, Lanzetta G, Capone L, Giraffa M, Russo I, Cicone F, Bozzao A, Alongi F, Nicosia L, Fineschi G, Marchetti L, Tufo T, Bianciardi F, Esposito V, Gentile P, Paolini S. Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases. J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003730. PMID: 34949695.
Copy Download .nbib Format: NLM
Erratum to "30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease" [Lung Cancer 122 (2018) 165-170].

Lung cancer (Amsterdam, Netherlands)

Osti MF, Agolli L, Valeriani M, Reverberi C, Braccia S, Marinelli L, De Sanctis V, Cortesi E, Martelli M, De Dominicis C, Minniti G, Nicosia L.
PMID: 34030912
Lung Cancer. 2021 Jul;157:168. doi: 10.1016/j.lungcan.2021.05.008. Epub 2021 May 24.

No abstract available.

Cite
Osti MF, Agolli L, Valeriani M, et al. Erratum to "30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease" [Lung Cancer 122 (2018) 165-170]. Lung Cancer. 2021;157:168doi: 10.1016/j.lungcan.2021.05.008.
Osti, M. F., Agolli, L., Valeriani, M., Reverberi, C., Braccia, S., Marinelli, L., De Sanctis, V., Cortesi, E., Martelli, M., De Dominicis, C., Minniti, G., & Nicosia, L. (2021). Erratum to "30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease" [Lung Cancer 122 (2018) 165-170]. Lung cancer (Amsterdam, Netherlands), 157168. https://doi.org/10.1016/j.lungcan.2021.05.008
Osti, M F, et al. "Erratum to "30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease" [Lung Cancer 122 (2018) 165-170]." Lung cancer (Amsterdam, Netherlands) vol. 157 (2021): 168. doi: https://doi.org/10.1016/j.lungcan.2021.05.008
Osti MF, Agolli L, Valeriani M, Reverberi C, Braccia S, Marinelli L, De Sanctis V, Cortesi E, Martelli M, De Dominicis C, Minniti G, Nicosia L. Erratum to "30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease" [Lung Cancer 122 (2018) 165-170]. Lung Cancer. 2021 Jul;157:168. doi: 10.1016/j.lungcan.2021.05.008. Epub 2021 May 24. PMID: 34030912.
Copy Download .nbib Format: NLM
MET overexpression and gene amplification in NSCLC: a clinical perspective.

Lung Cancer (Auckland, N.Z.)

Landi L, Minuti G, D'Incecco A, Salvini J, Cappuzzo F.
PMID: 28210131
Lung Cancer (Auckl). 2013 Jun 18;4:15-25. doi: 10.2147/LCTT.S35168. eCollection 2013.

The transmembrane tyrosine kinase mesenchymal-epidermal transition (MET) receptor and its ligand, hepatocyte growth factor, also known as scatter factor, have recently been identified as novel promising targets in several human malignancies, including non-small cell lung cancer (NSCLC). Amplification, mutation,...

Cite
Landi L, Minuti G, D'Incecco A, et al. MET overexpression and gene amplification in NSCLC: a clinical perspective. Lung Cancer (Auckl). 2013;4:15-25doi: 10.2147/LCTT.S35168.
Landi, L., Minuti, G., D'Incecco, A., Salvini, J., & Cappuzzo, F. (2013). MET overexpression and gene amplification in NSCLC: a clinical perspective. Lung Cancer (Auckland, N.Z.), 415-25. https://doi.org/10.2147/LCTT.S35168
Landi, Lorenza, et al. "MET overexpression and gene amplification in NSCLC: a clinical perspective." Lung Cancer (Auckland, N.Z.) vol. 4 (2013): 15-25. doi: https://doi.org/10.2147/LCTT.S35168
Landi L, Minuti G, D'Incecco A, Salvini J, Cappuzzo F. MET overexpression and gene amplification in NSCLC: a clinical perspective. Lung Cancer (Auckl). 2013 Jun 18;4:15-25. doi: 10.2147/LCTT.S35168. eCollection 2013. PMID: 28210131; PMCID: PMC5217438.
Copy Download .nbib Format: NLM
Imaging follow-up after liver transplantation.

The British journal of radiology

Di Martino M, Rossi M, Mennini G, Melandro F, Anzidei M, De Vizio S, Koryukova K, Catalano C.
PMID: 27188846
Br J Radiol. 2016 Aug;89(1064):20151025. doi: 10.1259/bjr.20151025. Epub 2016 Jun 10.

Liver transplantation (LT) represents the best treatment for end-stage chronic liver disease, acute liver failure and early stages of hepatocellular carcinoma. Radiologists should be aware of surgical techniques to distinguish a normal appearance from pathological findings. Imaging modalities, such...

Cite
Di Martino M, Rossi M, Mennini G, et al. Imaging follow-up after liver transplantation. Br J Radiol. 2016;89(1064):20151025doi: 10.1259/bjr.20151025.
Di Martino, M., Rossi, M., Mennini, G., Melandro, F., Anzidei, M., De Vizio, S., Koryukova, K., & Catalano, C. (2016). Imaging follow-up after liver transplantation. The British journal of radiology, 89(1064), 20151025. https://doi.org/10.1259/bjr.20151025
Di Martino, Michele, et al. "Imaging follow-up after liver transplantation." The British journal of radiology vol. 89,1064 (2016): 20151025. doi: https://doi.org/10.1259/bjr.20151025
Di Martino M, Rossi M, Mennini G, Melandro F, Anzidei M, De Vizio S, Koryukova K, Catalano C. Imaging follow-up after liver transplantation. Br J Radiol. 2016 Aug;89(1064):20151025. doi: 10.1259/bjr.20151025. Epub 2016 Jun 10. PMID: 27188846; PMCID: PMC5124875.
Copy Download .nbib Format: NLM
Patient-focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease.

American journal of hematology

Bradford C, Miodownik H, Thomas M, Ogu UO, Minniti CP.
PMID: 34914130
Am J Hematol. 2021 Dec 15; doi: 10.1002/ajh.26438. Epub 2021 Dec 15.

No abstract available.

Cite
Bradford C, Miodownik H, Thomas M, et al. Patient-focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease. Am J Hematol. 2021;doi: 10.1002/ajh.26438.
Bradford, C., Miodownik, H., Thomas, M., Ogu, U. O., & Minniti, C. P. (2021). Patient-focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease. American journal of hematology, . https://doi.org/10.1002/ajh.26438
Bradford, Christopher, et al. "Patient-focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease." American journal of hematology vol. (2021). doi: https://doi.org/10.1002/ajh.26438
Bradford C, Miodownik H, Thomas M, Ogu UO, Minniti CP. Patient-focused inquiry on hydroxyurea therapy adherence and reasons for discontinuation in adults with sickle cell disease. Am J Hematol. 2021 Dec 15; doi: 10.1002/ajh.26438. Epub 2021 Dec 15. PMID: 34914130.
Copy Download .nbib Format: NLM
Voxelotor use in adults with sickle cell disease in a real-world setting.

American journal of hematology

Curtis SA, Betancourt J, Kottapalli N, Campbell S, Minniti C.
PMID: 34967959
Am J Hematol. 2021 Dec 30; doi: 10.1002/ajh.26453. Epub 2021 Dec 30.

No abstract available.

Cite
Curtis SA, Betancourt J, Kottapalli N, et al. Voxelotor use in adults with sickle cell disease in a real-world setting. Am J Hematol. 2021;doi: 10.1002/ajh.26453.
Curtis, S. A., Betancourt, J., Kottapalli, N., Campbell, S., & Minniti, C. (2021). Voxelotor use in adults with sickle cell disease in a real-world setting. American journal of hematology, . https://doi.org/10.1002/ajh.26453
Curtis, Susanna A, et al. "Voxelotor use in adults with sickle cell disease in a real-world setting." American journal of hematology vol. (2021). doi: https://doi.org/10.1002/ajh.26453
Curtis SA, Betancourt J, Kottapalli N, Campbell S, Minniti C. Voxelotor use in adults with sickle cell disease in a real-world setting. Am J Hematol. 2021 Dec 30; doi: 10.1002/ajh.26453. Epub 2021 Dec 30. PMID: 34967959.
Copy Download .nbib Format: NLM
Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma.

JAMA surgery

Halazun KJ, Rosenblatt RE, Mehta N, Lai Q, Hajifathalian K, Gorgen A, Brar G, Sasaki K, Doyle MBM, Tabrizian P, Agopian VG, Najjar M, Ivanics T, Samstein B, Brown RS, Emond JC, Yao F, Lerut J, Rossi M, Mennini G, Iesari S, Finkenstedt A, Schaefer B, Mittler J, Hoppe-Lotichius M, Quintini C, Aucejo F, Chapman W, Sapisochin G.
PMID: 33950167
JAMA Surg. 2021 Jun 01;156(6):559-567. doi: 10.1001/jamasurg.2021.0954.

IMPORTANCE: Accurate preoperative prediction of hepatocellular carcinoma (HCC) recurrence after liver transplant is the mainstay of selection tools used by transplant-governing bodies to discern candidacy for patients with HCC. Although progress has been made, few tools incorporate objective measures...

Cite
Halazun KJ, Rosenblatt RE, Mehta N, et al. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. JAMA Surg. 2021;156(6):559-567doi: 10.1001/jamasurg.2021.0954.
Halazun, K. J., Rosenblatt, R. E., Mehta, N., Lai, Q., Hajifathalian, K., Gorgen, A., Brar, G., Sasaki, K., Doyle, M. B. M., Tabrizian, P., Agopian, V. G., Najjar, M., Ivanics, T., Samstein, B., Brown, R. S., Emond, J. C., Yao, F., Lerut, J., Rossi, M., Mennini, G., Iesari, S., Finkenstedt, A., Schaefer, B., Mittler, J., Hoppe-Lotichius, M., Quintini, C., Aucejo, F., Chapman, W., & Sapisochin, G. (2021). Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. JAMA surgery, 156(6), 559-567. https://doi.org/10.1001/jamasurg.2021.0954
Halazun, Karim J, et al. "Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma." JAMA surgery vol. 156,6 (2021): 559-567. doi: https://doi.org/10.1001/jamasurg.2021.0954
Halazun KJ, Rosenblatt RE, Mehta N, Lai Q, Hajifathalian K, Gorgen A, Brar G, Sasaki K, Doyle MBM, Tabrizian P, Agopian VG, Najjar M, Ivanics T, Samstein B, Brown RS, Emond JC, Yao F, Lerut J, Rossi M, Mennini G, Iesari S, Finkenstedt A, Schaefer B, Mittler J, Hoppe-Lotichius M, Quintini C, Aucejo F, Chapman W, Sapisochin G. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. JAMA Surg. 2021 Jun 01;156(6):559-567. doi: 10.1001/jamasurg.2021.0954. PMID: 33950167; PMCID: PMC8100910.
Copy Download .nbib Format: NLM
Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant.

JAMA surgery

Lai Q, Sapisochin G, Gorgen A, Vitale A, Halazun KJ, Iesari S, Schaefer B, Bhangui P, Mennini G, Wong TCL, Uemoto S, Lin CC, Mittler J, Ikegami T, Yang Z, Frigo AC, Zheng SS, Soejima Y, Hoppe-Lotichius M, Chen CL, Kaido T, Lo CM, Rossi M, Soin AS, Finkenstedt A, Emond JC, Cillo U, Lerut JP.
PMID: 34259797
JAMA Surg. 2021 Sep 01;156(9):e213112. doi: 10.1001/jamasurg.2021.3112. Epub 2021 Sep 08.

IMPORTANCE: Living-donor liver transplant (LDLT) offers advantages over deceased-donor liver transplant (DDLT) of improved intention-to-treat outcomes and management of the shortage of deceased-donor allografts. However, conflicting data still exist on the outcomes of LDLT in patients with hepatocellular carcinoma...

Cite
Lai Q, Sapisochin G, Gorgen A, et al. Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant. JAMA Surg. 2021;156(9):e213112doi: 10.1001/jamasurg.2021.3112.
Lai, Q., Sapisochin, G., Gorgen, A., Vitale, A., Halazun, K. J., Iesari, S., Schaefer, B., Bhangui, P., Mennini, G., Wong, T. C. L., Uemoto, S., Lin, C. C., Mittler, J., Ikegami, T., Yang, Z., Frigo, A. C., Zheng, S. S., Soejima, Y., Hoppe-Lotichius, M., Chen, C. L., Kaido, T., Lo, C. M., Rossi, M., Soin, A. S., Finkenstedt, A., Emond, J. C., Cillo, U., & Lerut, J. P. (2021). Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant. JAMA surgery, 156(9), e213112. https://doi.org/10.1001/jamasurg.2021.3112
Lai, Quirino, et al. "Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant." JAMA surgery vol. 156,9 (2021): e213112. doi: https://doi.org/10.1001/jamasurg.2021.3112
Lai Q, Sapisochin G, Gorgen A, Vitale A, Halazun KJ, Iesari S, Schaefer B, Bhangui P, Mennini G, Wong TCL, Uemoto S, Lin CC, Mittler J, Ikegami T, Yang Z, Frigo AC, Zheng SS, Soejima Y, Hoppe-Lotichius M, Chen CL, Kaido T, Lo CM, Rossi M, Soin AS, Finkenstedt A, Emond JC, Cillo U, Lerut JP. Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant. JAMA Surg. 2021 Sep 01;156(9):e213112. doi: 10.1001/jamasurg.2021.3112. Epub 2021 Sep 08. PMID: 34259797; PMCID: PMC8281041.
Copy Download .nbib Format: NLM
Soat2 ties cholesterol metabolism to β-oxidation and glucose tolerance in male mice.

Journal of internal medicine

Pramfalk C, Ahmed O, Pedrelli M, Minniti ME, Luquet S, Denis RG, Olin M, Härdfeldt J, Vedin LL, Steffensen KR, Rydén M, Hodson L, Eriksson M, Parini P.
PMID: 34982494
J Intern Med. 2022 Jan 04; doi: 10.1111/joim.13450. Epub 2022 Jan 04.

BACKGROUND: Sterol O-acyltransferase 2 (Soat2) encodes acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2), which synthesizes cholesteryl esters in hepatocytes and enterocytes fated either to storage or to secretion into nascent triglyceride-rich lipoproteins.OBJECTIVES: We aimed to unravel the molecular mechanisms leading to...

Cite
Pramfalk C, Ahmed O, Pedrelli M, et al. Soat2 ties cholesterol metabolism to β-oxidation and glucose tolerance in male mice. J Intern Med. 2022;doi: 10.1111/joim.13450.
Pramfalk, C., Ahmed, O., Pedrelli, M., Minniti, M. E., Luquet, S., Denis, R. G., Olin, M., Härdfeldt, J., Vedin, L. L., Steffensen, K. R., Rydén, M., Hodson, L., Eriksson, M., & Parini, P. (2022). Soat2 ties cholesterol metabolism to β-oxidation and glucose tolerance in male mice. Journal of internal medicine, . https://doi.org/10.1111/joim.13450
Pramfalk, Camilla, et al. "Soat2 ties cholesterol metabolism to β-oxidation and glucose tolerance in male mice." Journal of internal medicine vol. (2022). doi: https://doi.org/10.1111/joim.13450
Pramfalk C, Ahmed O, Pedrelli M, Minniti ME, Luquet S, Denis RG, Olin M, Härdfeldt J, Vedin LL, Steffensen KR, Rydén M, Hodson L, Eriksson M, Parini P. Soat2 ties cholesterol metabolism to β-oxidation and glucose tolerance in male mice. J Intern Med. 2022 Jan 04; doi: 10.1111/joim.13450. Epub 2022 Jan 04. PMID: 34982494.
Copy Download .nbib Format: NLM
Proarrhythmic Side of Cardiac Lipoma.

Circulation. Cardiovascular imaging

Genovese D, Gasparetto N, Favero L, Carrer A, Balestriero G, Calzolari V, De Mattia L, Zecchel R, Minniti G, Cernetti C.
PMID: 34711078
Circ Cardiovasc Imaging. 2021 Nov;14(11):e013301. doi: 10.1161/CIRCIMAGING.121.013301. Epub 2021 Oct 29.

No abstract available.

Cite
Genovese D, Gasparetto N, Favero L, et al. Proarrhythmic Side of Cardiac Lipoma. Circ Cardiovasc Imaging. 2021;14(11):e013301doi: 10.1161/CIRCIMAGING.121.013301.
Genovese, D., Gasparetto, N., Favero, L., Carrer, A., Balestriero, G., Calzolari, V., De Mattia, L., Zecchel, R., Minniti, G., & Cernetti, C. (2021). Proarrhythmic Side of Cardiac Lipoma. Circulation. Cardiovascular imaging, 14(11), e013301. https://doi.org/10.1161/CIRCIMAGING.121.013301
Genovese, Davide, et al. "Proarrhythmic Side of Cardiac Lipoma." Circulation. Cardiovascular imaging vol. 14,11 (2021): e013301. doi: https://doi.org/10.1161/CIRCIMAGING.121.013301
Genovese D, Gasparetto N, Favero L, Carrer A, Balestriero G, Calzolari V, De Mattia L, Zecchel R, Minniti G, Cernetti C. Proarrhythmic Side of Cardiac Lipoma. Circ Cardiovasc Imaging. 2021 Nov;14(11):e013301. doi: 10.1161/CIRCIMAGING.121.013301. Epub 2021 Oct 29. PMID: 34711078.
Copy Download .nbib Format: NLM
Showing 157 to 168 of 168 entries